ASCO 2024 | JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC

Michael Morris, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase I, first-in-human study (NCT04644770) evaluating JNJ-6420, an anti-hK2 antibody-based radiotherapy, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). Thrombocytopenia and interstitial lung disease were especially associated with repeated doses and durable responses were also noted, emphasizing hK2 as a promising target for prostate cancer therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.